Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $510K, compared with -$2.98M a year earlier. Trailing-twelve-month accounts payables was -$747K. Over 3 fiscal years it compounded at -22.8% a year.

Context

  • Accounts payables amounted to 3.5% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $510K or moves back toward the trailing-twelve-month quarterly average of -$186.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$510K+367.0% QoQ
Last fiscal yearDec 2025
-$4.24M-717.2% YoY
LTMMar 2026
-$747K-49.2% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+117.1%——
1 year-717.2%——
3-year CAGR-22.8%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(4.24M) USD
Year-over-year change
-717.2%

Accounts Payables vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -49.2% is the 5th highest of 10, against a peer median of -55.2%.
  • Accounts payables amounts to 3.2% of revenue for ATRA, versus a peer median of 22.1%.
ATRA Competitors
Accounts Payables for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IFRXInflaRx N.V.LTM Mar 2026€6.32M EUR—+17.8%21552.6%
OVIDOvid Therapeutics Inc.LTM Mar 2026$3.63M USD+320.5%-38.0%51.0%
STROSutro Biopharma, Inc.LTM Mar 2026$3.13M USD-534.1%+26.3%3.1%
MGNXMacroGenics, Inc.LTM Mar 2026$2.31M USD-48.2%-70.5%1.5%
CNTXContext Therapeutics Inc.LTM Mar 2026$1.46M USD+240.3%——
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$1.44M USD-64.1%——
COYACoya Therapeutics, Inc.LTM Mar 2026$783.6K USD-867.8%—9.9%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$747K USD-49.2%-22.8%3.2%
CSBRChampions Oncology, Inc.LTM Jan 2026$614K USD+567.4%—1.1%
STTKShattuck Labs, Inc.LTM Mar 2026$343K USD-64.3%-51.8%34.3%
CLNNClene Inc.LTM Mar 2026$104K USD-55.2%—77.6%
Peer median (excluding ATRA) —-55.2%-38.0%22.1%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.38M
Deferred Income Tax1.79M0000
Stock-Based Compensation53.87M53.84M45.39M27M9.75M
Change in Working Capital52.58M(61.47M)15.34M(30.96M)(104.74M)
Accounts Receivables264K(39.24M)6.11M32.63M229K
Inventory3.34M(1.59M)(8.12M)(4.43M)10.66M
Accounts Payables9.07M(9.21M)(3.13M)687K(4.24M)
Other Working Capital39.91M(11.44M)20.48M(59.84M)(111.38M)
Other Non-Cash Items2.04M(40.15M)17.59M15.59M8.98M
Operating Cash Flow(220.52M)(270.43M)(192.98M)(68.72M)(50.94M)
Capital Expenditures(10.58M)(4.19M)(1.22M)(246K)0
Acquisitions (Net)(32.84M)000948K
Purchases of Investments(301.13M)(180.59M)(83.65M)(19.67M)(7.89M)
Sales of Investments333.97M292.97M208.71M28.54M25.09M
Other Investing Activities32.84M94.77M25K00
Investing Cash Flow22.26M202.96M123.87M8.62M18.15M
Debt Repayment(254K)(518K)(947K)(892K)(250K)
Common Stock Issued98.7M21.89M2.14M59.95M16.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.5M31.71M821K223K(1K)
Financing Cash Flow103.94M53.08M2.01M59.28M16.1M
Effect of Forex Changes00000
Net Change in Cash(94.32M)(14.39M)(67.1M)(811K)(16.69M)
Free Cash Flow(231.1M)(274.62M)(194.2M)(68.96M)(50.94M)

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.